{"pressReleaseArticle":{"contentWrapper":{"title":"GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227, receives US FDA Breakthrough Therapy Designation in late-line relapsed or refractory osteosarcoma","intro":"","publishDateTime":"07/01/2025 00:00:00","publishDate":"January 07 2025","forInvestorsAndMediaOnlyText":"

Issued: London, UK

\r\n

For media and investors only

","shortDescription":"Regulatory designation based on promising early data in this rare bone cancer.","image":null,"downloadLink":{"text":"Download (PDF - 144.6KB)","href":"/media/yo2pq5kl/final-press-release-gsk227-btd-osteosarcoma.pdf","title":"Opens in a new window","target":"_blank"},"tags":[]},"components":[{"type":"rich-text","text":"\n

GSK plc (LSE/NYSE: GSK) announced today that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for GSK5764227 (GSK’227), its B7-H3-targeted antibody-drug conjugate (ADC) being evaluated for the treatment of adult patients with relapsed or refractory osteosarcoma (bone cancer) who have progressed on at least two prior lines of therapy. The Breakthrough Therapy Designation aims to expedite the development and review of drugs with the potential to treat a serious condition and where preliminary clinical evidence may indicate substantial improvement over currently available therapy.1 This is the third regulatory designation for GSK’227, following the European Medicines Agency’s decision to grant Priority Medicines (PRIME) designation and the FDA’s decision to grant Breakthrough Therapy Designation for relapsed or refractory extensive-stage small-cell lung cancer in August 2024 and December 2024, respectively.2,3

\n

Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: “This latest regulatory designation for GSK’227 exemplifies the potential of our targeted ADC in patients with difficult to treat cancers. For patients with relapsed or refractory osteosarcoma, there is an urgent unmet medical need with no approved treatment options once the cancer returns a second time, and chemotherapy provides limited benefit in this setting.”

\n

The US FDA’s Breakthrough Therapy Designation is supported by data from the ARTEMIS-002 study. This is a phase II, open-label, randomised, multi-centre, clinical trial evaluating the efficacy and safety of GSK’227 in patients with relapsed or refractory osteosarcoma and other unresectable bone and soft tissue sarcomas, conducted by Hansoh Pharma. More than 60 patients were enrolled, including 42 patients with osteosarcoma. Results from ARTEMIS-002 were presented at the 2024 American Society of Clinical Oncology Annual Meeting.4 Last year, GSK acquired exclusive worldwide rights (excluding China’s mainland, Hong Kong, Macau, and Taiwan) from Hansoh Pharma to progress clinical development and commercialisation of GSK’227. GSK recently began a global phase I trial (NCT06551142) as a part of the development plan to support a registrational pathway for GSK’227.

\n

Osteosarcoma mainly affects children and young adults and is the most common primary bone cancer, accounting for 20-40% of all bone cancers.5 It is a rare disease with an annual incidence of 3.3 patients per million in the US, representing less than 1% of all new cancer diagnoses.6,7 Approximately 20-30% of patients who present with localised (non-metastatic) osteosarcoma and 80% of those who present with metastatic osteosarcoma experience relapsed or refractory disease.8 Following first-line chemotherapy, treatment options for patients with relapsed or refractory osteosarcoma are severely limited, with no clear standard of care available.9 After patients progress on two prior lines of treatment, options become even more limited, with no approved therapies.

\n

About GSK’227

\n

GSK’227, also known as HS-20093, is a novel investigational B7-H3-targeted antibody-drug conjugate composed of a fully human anti-B7-H3 monoclonal antibody covalently linked to a topoisomerase inhibitor payload. HS-20093 is being developed by Hansoh Pharma for the treatment of lung cancer, sarcoma, head and neck cancers and other solid tumours in multiple phase I, II and III clinical trials in China. GSK’s global phase I trial for GSK’227 began in August 2024.

\n

GSK in oncology

\n

Oncology is an emerging therapeutic area for GSK where we are committed to maximising patient survival with a current focus on haematologic malignancies, gynaecologic cancers, and other solid tumours through breakthroughs in immuno-oncology and tumour-cell targeting therapies.

\n

About GSK

\n

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.

\n

Cautionary statement regarding forward-looking statements

\n

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D “Risk factors” in GSK’s Annual Report on Form 20-F for 2023, and GSK’s Q3 Results for 2024.

","useGreyBackground":false,"fullWidth":false},{"type":"references","title":"References","references":[{"anchorName":"1","text":"

US Food and Drug Administration. Breakthrough Therapy. Available at: https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/breakthrough-therapy

"},{"anchorName":"2","text":"

GSK. GSK receives US FDA Breakthrough Therapy Designation for its B7-H3-targeted antibody-drug conjugate in relapsed or refractory extensive-stage small-cell lung cancer. Available at: https://www.gsk.com/en-gb/media/press-releases/gsk-receives-us-fda-breakthrough-therapy-designation/.

"},{"anchorName":"3","text":"

GSK. GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227, receives EMA Priority Medicines (PRIME) Designation in relapsed extensive-stage small-cell lung cancer. Available at: https://www.gsk.com/en-gb/media/press-releases/b7-h3-targeted-antibody-drug-conjugate-receives-ema-priority-medicines-designation-in-relapsed-extensive-stage-small-cell-lung-cancer/.

"},{"anchorName":"4","text":"

Lu Xie et al., ARTEMIS-002: Phase 2 study of HS-20093 in patients with relapsed or refractory osteosarcoma JCO 42, 11507-11507(2024). DOI:10.1200/JCO.2024.42.16_suppl.11507

"},{"anchorName":"5","text":"

Valery PC, Laversanne M, Bray F. Bone cancer incidence by morphological subtype: a global assessment. Cancer Causes Control. 2015;26(8):1127-39.

"},{"anchorName":"6","text":"

Cole S, Gianferante DM, Zhu B, et al. Osteosarcoma: A surveillance, epidemiology, and end results program-based analysis from 1975 to 2017. Cancer. 2022;128(11):2107-18.

"},{"anchorName":"7","text":"

Mirabello L, Troisi RJ, Savage SA. International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer. 2009;125(1):229-34.

"},{"anchorName":"8","text":"

Durfee RA, Mohammed M, Luu HH. Review of Osteosarcoma and Current Management. Rheumatol Ther. 2016 Dec;3(2):221-243. doi: 10.1007/s40744-016-0046-y. Epub 2016 Oct 19. PMID: 27761754; PMCID: PMC5127970.

"},{"anchorName":"9","text":"

National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology (NCCN Guidelines): bone cancer. August 20, 2024. Version 1.2025. Accessed 24 October 2024. https://www.nccn.org/professionals/physician_gls/pdf/bone.pdf.

"}]},{"type":"varied-signpost-grid","title":"You might also like","layoutPattern":4,"pages":[{"title":"Company","content":"We unite science, technology and talent to get ahead of disease together","image":{"src":"/media/suilv4ve/dna-and-tech-science-image-rgb.jpg?width=427&height=533&format=webp&quality=100&v=1dcd7c357a61910","alt":"DNA And Tech Science Image","darkModeSrc":"/media/suilv4ve/dna-and-tech-science-image-rgb.jpg?width=427&height=533&format=webp&quality=90&v=1dcd7c357a61910"},"link":{"text":"Company","href":"/en-us/company/","openInNewWindowText":null}},{"title":"Media contacts","content":"Contact our GSK US Media Team. We are committed to responding to the information needs of the media as quickly as possible","image":{"src":"/media/k2xl0f3e/one-person-in-front-of-media-section-3.jpg?rxy=0.4483333333333333,0.94375&width=427&height=533&format=webp&quality=100&v=1dbe12268273820","alt":"men in front of media station ","darkModeSrc":"/media/k2xl0f3e/one-person-in-front-of-media-section-3.jpg?rxy=0.4483333333333333,0.94375&width=427&height=533&format=webp&quality=90&v=1dbe12268273820"},"link":{"text":"Media contacts","href":"/en-us/media/media-contacts/","openInNewWindowText":null}},{"title":"Press releases","content":"Keep up to date with our news and recent announcements","image":{"src":"/media/viygjccz/person-getting-interviewed-2.jpg?rxy=0.46666666666666667,0.69125&width=427&height=533&format=webp&quality=100&v=1dbe122680aaf70","alt":"two people on air.","darkModeSrc":"/media/viygjccz/person-getting-interviewed-2.jpg?rxy=0.46666666666666667,0.69125&width=427&height=533&format=webp&quality=90&v=1dbe122680aaf70"},"link":{"text":"Press releases","href":"/en-us/media/press-releases/","openInNewWindowText":null}}],"hidePageDescription":false,"useGreyBackground":false}]},"id":5227,"docCheckLogout":null,"pageType":"pressReleasePage","languageCode":"en-US","theme":"light","breadcrumb":{"ariaLabel":"Breadcrumb","links":[{"text":"Home","href":"/en-us/","openInNewWindowText":null},{"text":"Media","href":"/en-us/media/","openInNewWindowText":null},{"text":"Press releases","href":"/en-us/media/press-releases/","openInNewWindowText":null},{"text":"GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227, receives US FDA Breakthrough Therapy Designation in late-line relapsed or refractory osteosarcoma","href":"/en-us/media/press-releases/gsk-b7-h3-targeted-antibody-drug-conjugate-gsk227-receives-us-fda-breakthrough-therapy-designation-in-late-line-relapsed-or-refractory-osteosarcoma/","openInNewWindowText":null}]},"pageName":"GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227, receives US FDA Breakthrough Therapy Designation in late-line relapsed or refractory osteosarcoma","topNav":{"homeLink":{"text":"GSK Homepage","href":"/en-us/","openInNewWindowText":null},"topBar":{"currentLocation":{"isGlobal":false,"text":"United States (EN)"},"languageSelector":{"currentLanguage":null,"currentLanguageMobile":null,"selectableLanguages":[]},"darkModeSwitch":{"text":"Dark Mode","tooltipText":"

Switch to dark mode to head towards a more sustainable world together. More info

"},"globalSiteLink":{"text":"Global","href":"https://www.gsk.com","target":"_blank","openInNewWindowText":"Opens in a new window"},"locationSelector":{"text":"Change location","href":"/en-us/locations/","openInNewWindowText":null},"healthCareLink":{"text":"Healthcare professionals","href":"https://gskpro.com","target":"_blank","openInNewWindowText":"Opens in a new window"},"contactUs":{"text":"Contact us","href":"/en-us/contact-us/","openInNewWindowText":null},"search":"Search","backToMain":"Back to main","menu":"Menu","closeMenu":"Close menu","animationsToggleModel":{"enable":true,"activeText":"Pause video","inactiveText":"Play video"}},"nodes":[{"tooltip":null,"hasBorderRight":true,"title":"Behind the Science US edition","url":"/en-us/behind-the-science-us-edition/","nodes":[],"isActive":false,"promos":[]},{"tooltip":null,"hasBorderRight":false,"title":"Company","url":"/en-us/company/","nodes":[{"title":"Purpose, strategy and culture","url":"/en-us/company/purpose-strategy-and-culture/","nodes":[],"isActive":false},{"title":"Respiratory, immunology and inflammation","url":"/en-us/company/respiratory-immunology-and-inflammation/","nodes":[],"isActive":false},{"title":"Oncology","url":"/en-us/company/oncology/","nodes":[{"title":"Myelofibrosis","url":"/en-us/company/oncology/myelofibrosis/","nodes":[],"isActive":false},{"title":"Ovarian cancer","url":"/en-us/company/oncology/ovarian-cancer/","nodes":[],"isActive":false},{"title":"Endometrial cancer","url":"/en-us/company/oncology/endometrial-cancer/","nodes":[],"isActive":false},{"title":"Multiple myeloma","url":"/en-us/company/oncology/multiple-myeloma/","nodes":[],"isActive":false},{"title":"Rectal cancer","url":"/en-us/company/oncology/rectal-cancer/","nodes":[],"isActive":false}],"isActive":false},{"title":"HIV","url":"/en-us/company/hiv/","nodes":[],"isActive":false},{"title":"Infectious diseases","url":"/en-us/company/infectious-diseases/","nodes":[{"title":"Vaccines","url":"/en-us/company/infectious-diseases/vaccines/","nodes":[],"isActive":false},{"title":"Flu","url":"/en-us/company/infectious-diseases/flu/","nodes":[],"isActive":false},{"title":"Shingles (Herpes Zoster)","url":"/en-us/company/infectious-diseases/shingles-herpes-zoster/","nodes":[],"isActive":false},{"title":"RSV (Respiratory Syncytial Virus)","url":"/en-us/company/infectious-diseases/rsv-respiratory-syncytial-virus/","nodes":[],"isActive":false},{"title":"Meningitis","url":"/en-us/company/infectious-diseases/meningitis/","nodes":[],"isActive":false}],"isActive":false}],"isActive":false,"promos":[{"text":"Global Outstanding people","image":{"src":"/media/kjtduuwb/20250115-extra-6-phl-small.jpg?width=329&height=185&format=webp&quality=100&v=1dbe12238ee2370","alt":"Two people walking in an office","darkModeSrc":"/media/kjtduuwb/20250115-extra-6-phl-small.jpg?width=329&height=185&format=webp&quality=90&v=1dbe12238ee2370"},"link":{"text":"Spotlight on","href":"https://www.gsk.com/en-gb/company/outstanding-people/","target":"_blank","openInNewWindowText":"Opens in a new window"}},{"text":"Global policy positions","image":{"src":"/media/diaofnw2/20250115-extra-14-phl.jpg?width=329&height=185&format=webp&quality=100&v=1dbe122233e8880","alt":"An employee attending an online meeting","darkModeSrc":"/media/diaofnw2/20250115-extra-14-phl.jpg?width=329&height=185&format=webp&quality=90&v=1dbe122233e8880"},"link":{"text":"Spotlight on","href":"https://www.gsk.com/en-gb/company/policy-positions","target":"_blank","openInNewWindowText":"Opens in a new window"}}]},{"tooltip":null,"hasBorderRight":false,"title":"Innovation","url":"/en-us/innovation/","nodes":[{"title":"Therapeutic areas","url":"/en-us/innovation/therapeutic-areas/","nodes":[],"isActive":false},{"title":"Technologies","url":"/en-us/innovation/technologies/","nodes":[],"isActive":false},{"title":"Clinical studies","url":"/en-us/innovation/clinical-studies/","nodes":[{"title":"Representative clinical trials","url":"/en-us/innovation/clinical-studies/representative-clinical-trials/","nodes":[],"isActive":false}],"isActive":false}],"isActive":false,"promos":[{"text":"Global pipeline","image":{"src":"/media/zr0acsx2/20281231-c1-innovation-um.jpg?width=329&height=185&format=webp&quality=100&v=1dc8fa7a9f728d0","alt":"A close-up shot of scientist's hands handling a vial","darkModeSrc":"/media/zr0acsx2/20281231-c1-innovation-um.jpg?width=329&height=185&format=webp&quality=90&v=1dc8fa7a9f728d0"},"link":{"text":"Spotlight on","href":"https://www.gsk.com/en-gb/innovation/pipeline/","target":"_blank","openInNewWindowText":"Opens in a new window"}},{"text":"Global Behind the science magazine","image":{"src":"/media/vvwddvsg/gsk_tech_human_image_6k.jpg?width=329&height=185&format=webp&quality=100&v=1dcc04016a69c90","alt":"GSK Tech Human Image","darkModeSrc":"/media/vvwddvsg/gsk_tech_human_image_6k.jpg?width=329&height=185&format=webp&quality=90&v=1dcc04016a69c90"},"link":{"text":"Spotlight on","href":"https://www.gsk.com/en-gb/behind-the-science-magazine/","target":"_blank","openInNewWindowText":"Opens in a new window"}}]},{"tooltip":null,"hasBorderRight":false,"title":"Products","url":"/en-us/products/","nodes":[],"isActive":false,"promos":[]},{"tooltip":null,"hasBorderRight":true,"title":"Responsibility","url":"/en-us/responsibility/","nodes":[{"title":"Inclusion","url":"/en-us/responsibility/inclusion/","nodes":[],"isActive":false},{"title":"US charitable investments","url":"/en-us/responsibility/us-charitable-investments/","nodes":[{"title":"Charitable grants","url":"/en-us/responsibility/us-charitable-investments/charitable-grants/","nodes":[],"isActive":false}],"isActive":false},{"title":"Ethical standards","url":"/en-us/responsibility/ethical-standards/","nodes":[],"isActive":false}],"isActive":false,"promos":[{"text":"Access to medicines","image":{"src":"/media/q2cllvad/20271231-a1-careers-up.jpg?width=329&height=185&format=webp&quality=100&v=1dbe1221dd270f0","alt":"A scientist checking experiment results in the lab","darkModeSrc":"/media/q2cllvad/20271231-a1-careers-up.jpg?width=329&height=185&format=webp&quality=90&v=1dbe1221dd270f0"},"link":{"text":"FEATURED WEBSITE","href":"https://www.gskforyou.com/","openInNewWindowText":null}},{"text":"Global Responsibility ","image":{"src":"/media/e5nbvffs/20250115-f4-ethical-standards-um.jpg?width=329&height=185&format=webp&quality=100&v=1dbe1221ed9f5e0","alt":"A smiling scientist posing in the lab","darkModeSrc":"/media/e5nbvffs/20250115-f4-ethical-standards-um.jpg?width=329&height=185&format=webp&quality=90&v=1dbe1221ed9f5e0"},"link":{"text":"Spotlight on","href":"https://www.gsk.com/en-gb/responsibility/","target":"_blank","openInNewWindowText":"Opens in a new window"}}]},{"tooltip":null,"hasBorderRight":false,"title":"Media","url":"/en-us/media/","nodes":[{"title":"Press releases","url":"/en-us/media/press-releases/","nodes":[],"isActive":true},{"title":"Media contacts","url":"/en-us/media/media-contacts/","nodes":[],"isActive":false},{"title":"In Focus","url":"/en-us/media/in-focus/","nodes":[{"title":"Flu is a Family Affair","url":"/en-us/media/in-focus/flu-is-a-family-affair/","nodes":[],"isActive":false},{"title":"Five for Five","url":"/en-us/media/in-focus/five-for-five/","nodes":[],"isActive":false}],"isActive":false}],"isActive":true,"promos":[{"text":"Global press releases","image":{"src":"/media/svplhxgn/20271231-h2-visit-our-global-careers-site-link-um.jpg?width=329&height=185&format=webp&quality=100&v=1dbe12238bed610","alt":"Two employees discussing work in the office","darkModeSrc":"/media/svplhxgn/20271231-h2-visit-our-global-careers-site-link-um.jpg?width=329&height=185&format=webp&quality=90&v=1dbe12238bed610"},"link":{"text":"Spotlight on","href":"https://www.gsk.com/en-gb/media/press-releases/","target":"_blank","openInNewWindowText":"Opens in a new window"}}]},{"tooltip":null,"hasBorderRight":false,"title":"Careers","url":"/en-us/careers/","nodes":[{"title":"Search jobs","url":"/en-us/careers/search-jobs/","nodes":[],"isActive":false},{"title":"Life at GSK","url":"/en-us/careers/life-at-gsk/","nodes":[{"title":"Employment rights under federal law","url":"/en-us/careers/life-at-gsk/employment-rights-under-federal-law/","nodes":[],"isActive":false}],"isActive":false},{"title":"Experienced professionals","url":"/en-us/careers/experienced-professionals/","nodes":[{"title":"A career in oncology","url":"/en-us/careers/experienced-professionals/a-career-in-oncology/","nodes":[],"isActive":false},{"title":"A career in Boston","url":"/en-us/careers/experienced-professionals/a-career-in-boston/","nodes":[],"isActive":false}],"isActive":false},{"title":"Early careers","url":"/en-us/careers/early-careers/","nodes":[{"title":"Apprentices","url":"/en-us/careers/early-careers/apprentices/","nodes":[],"isActive":false},{"title":"Internships and co-ops","url":"/en-us/careers/early-careers/internships-and-co-ops/","nodes":[],"isActive":false},{"title":"Scientific leadership program","url":"/en-us/careers/early-careers/scientific-leadership-program/","nodes":[],"isActive":false},{"title":"Commercial development program","url":"/en-us/careers/early-careers/commercial-development-program/","nodes":[],"isActive":false}],"isActive":false},{"title":"Veterans at GSK","url":"/en-us/careers/veterans-at-gsk/","nodes":[],"isActive":false}],"isActive":false,"promos":[{"text":"Global how we hire","image":{"src":"/media/3u2dneiw/20271231-a3-contact-us-phl.jpg?width=329&height=185&format=webp&quality=100&v=1dbe12236d41d10","alt":"Three employees meeting in the office","darkModeSrc":"/media/3u2dneiw/20271231-a3-contact-us-phl.jpg?width=329&height=185&format=webp&quality=90&v=1dbe12236d41d10"},"link":{"text":"Spotlight on","href":"https://www.gsk.com/en-gb/careers/how-we-hire/","openInNewWindowText":null}},{"text":"Global graduate program","image":{"src":"/media/xrsfni0a/20281231-h4a-achieve-your-career-goals-up.jpg?width=329&height=185&format=webp&quality=100&v=1dbe1221e21c970","alt":"A smiling scientist posing in the lab","darkModeSrc":"/media/xrsfni0a/20281231-h4a-achieve-your-career-goals-up.jpg?width=329&height=185&format=webp&quality=90&v=1dbe1221e21c970"},"link":{"text":"Spotlight on","href":"https://www.gsk.com/en-gb/careers/early-talent/future-leaders-graduate-programme","openInNewWindowText":null}}]}],"skipToContent":null,"skipToSearch":null,"typeaheadSearch":{"apiEndpoint":"api/search/typeahead?siteContainerId=1702","searchFieldPlaceholderText":"Enter a search term...","searchPage":"/en-us/search/","ariaLabel":"Submit form"},"ariaLabel":"Global navigation"},"footer":{"logo":null,"copyrightText":"

This is our US website, intended for US audiences only. Other market sites can be reached by visiting our location selector.

\n

© 2001-2026 GSK plc. All rights reserved. Trade marks are owned by or licensed to the GSK group of companies.

\n

GSK plc. Registered in England and Wales No. 3888792.

\n

Registered office: 79 New Oxford Street, London. United Kingdom. WC1A 1DG

","modernSlaveryStatement":null,"sections":{"socialMedia":{"columnTitle":"Follow us on:","socialMediaItems":[{"globalLink":{"text":null,"href":"http://www.linkedin.com/company/glaxosmithkline","target":"_blank","openInNewWindowText":"Opens in a new window"},"localLink":null,"ariaLabel":"Follow us on LinkedIn","customIcon":null,"showPopupMenu":false,"type":"LinkedIn"},{"globalLink":{"text":null,"href":"https://www.instagram.com/gskus?igsh=dDl0NjZmbmlia3F1","target":"_blank","openInNewWindowText":"Opens in a new window"},"localLink":null,"ariaLabel":"Follow us on Instagram","customIcon":null,"showPopupMenu":false,"type":"Instagram"},{"globalLink":{"text":null,"href":"https://www.threads.com/@gskus","target":"_blank","openInNewWindowText":"Opens in a new window"},"localLink":null,"ariaLabel":"Follow us on Threads","customIcon":null,"showPopupMenu":false,"type":"Threads"},{"globalLink":{"text":null,"href":"https://www.facebook.com/GSK","target":"_blank","openInNewWindowText":"Opens in a new window"},"localLink":null,"ariaLabel":"Follow us on Facebook","customIcon":null,"showPopupMenu":false,"type":"Facebook"},{"globalLink":{"text":null,"href":"http://www.youtube.com/GSK","target":"_blank","openInNewWindowText":"Opens in a new window"},"localLink":null,"ariaLabel":"Follow us on Youtube","customIcon":null,"showPopupMenu":false,"type":"Youtube"}]},"columns":[{"columnTitle":"GSK websites","links":[{"text":"GSK Global website","href":"https://www.gsk.com","target":"_blank","openInNewWindowText":"Opens in a new window"},{"text":"Locations selector","href":"/en-us/locations/","openInNewWindowText":null},{"text":"Global Behind the science","href":"https://www.gsk.com/en-gb/behind-the-science/","target":"_blank","openInNewWindowText":"Opens in a new window"},{"text":"GSKPro for HCPs","href":"https://gskpro.com","target":"_blank","openInNewWindowText":"Opens in a new window"},{"text":"ViiV Healthcare","href":"https://viivhealthcare.com/","target":"_blank","openInNewWindowText":"Opens in a new window"},{"text":"GSK study register","href":"https://www.gsk-studyregister.com/en/","target":"_blank","openInNewWindowText":"Opens in a new window"},{"text":"Business to Business","href":"/en-us/business-to-business-in-the-us/","openInNewWindowText":null},{"text":"Supplier website","href":"https://supplier.gsk.com/","target":"_blank","openInNewWindowText":"Opens in a new window"}]},{"columnTitle":"Quick links","links":[{"text":"Behind the science US edition","href":"/en-us/behind-the-science-us-edition/","openInNewWindowText":null},{"text":"Company","href":"/en-us/company/","openInNewWindowText":null},{"text":"Innovation","href":"/en-us/innovation/","openInNewWindowText":null},{"text":"Products","href":"/en-us/products/","openInNewWindowText":null},{"text":"Responsibility","href":"/en-us/responsibility/","openInNewWindowText":null},{"text":"Media","href":"/en-us/media/","openInNewWindowText":null},{"text":"Careers","href":"/en-us/careers/","openInNewWindowText":null}]},{"columnTitle":"Global investors","links":[{"text":"Shareholders","href":"https://www.gsk.com/en-gb/investors/","target":"_blank","openInNewWindowText":"Opens in a new window"},{"text":"Quarterly results","href":"https://www.gsk.com/en-gb/investors/quarterly-results/","target":"_blank","openInNewWindowText":"Opens in a new window"},{"text":"Financial reports","href":"https://www.gsk.com/en-gb/investors/financial-reports/","target":"_blank","openInNewWindowText":"Opens in a new window"},{"text":"Share price analysis","href":"https://www.gsk.com/en-gb/investors/dividend-and-share-price/","openInNewWindowText":null},{"text":"Product pipeline","href":"https://www.gsk.com/en-gb/innovation/pipeline/","target":"_blank","openInNewWindowText":"Opens in a new window"}]},{"columnTitle":"Get in touch","links":[{"text":"Contact us","href":"/en-us/contact-us/","openInNewWindowText":null},{"text":"Report a possible side effect","href":"/en-us/report-a-possible-side-effect/","openInNewWindowText":null},{"text":"GSK Speak up","href":"https://www.gsk.com/speakup","target":"_blank","openInNewWindowText":"Opens in a new window"}]}]},"bottomLinks":[{"text":"Accessibility","href":"/en-us/accessibility/","openInNewWindowText":null},{"text":"Digital sustainability","href":"/en-us/digital-sustainability/","openInNewWindowText":null},{"text":"Terms of use","href":"/en-us/terms-of-use/","openInNewWindowText":null},{"text":"Cookie policy","href":"/en-us/cookie-policy/","openInNewWindowText":null},{"text":"Privacy notice","href":"https://privacy.gsk.com/en-us/privacy-notice/","target":"_blank","openInNewWindowText":"Opens in a new window"},{"text":"Sitemap","href":"/en-us/sitemap/","openInNewWindowText":null}],"continueToLink":null,"legalApprovalText":""},"sharing":{"description":"Regulatory designation based on promising early data in this rare bone cancer.","og":[{"property":"og:title","content":"GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227, receives US FDA Breakthrough Therapy Designation in late-line relapsed or refractory osteosarcoma"},{"property":"og:description","content":"Regulatory designation based on promising early data in this rare bone cancer."},{"property":"og:image","content":"https://us.gsk.com/media/gdvhctix/scientist-testing-biological-samples.jpg?width=600&format=webp&quality=100&v=1dcc1f03f5ccb30"},{"property":"og:url","content":"https://us.gsk.com/en-us/media/press-releases/gsk-b7-h3-targeted-antibody-drug-conjugate-gsk227-receives-us-fda-breakthrough-therapy-designation-in-late-line-relapsed-or-refractory-osteosarcoma/"}],"twitter":[{"name":"twitter:card","content":"summary_large_image"},{"name":"twitter:site","content":"@gsk"},{"name":"twitter:title","content":"GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227, receives US FDA Breakthrough Therapy Designation in late-line relapsed or refractory osteosarcoma"},{"name":"twitter:description","content":"Regulatory designation based on promising early data in this rare bone cancer."},{"name":"twitter:image","content":"https://us.gsk.com/media/gdvhctix/scientist-testing-biological-samples.jpg?width=600&format=webp&quality=100&v=1dcc1f03f5ccb30"},{"name":"twitter:url","content":"https://us.gsk.com/en-us/media/press-releases/gsk-b7-h3-targeted-antibody-drug-conjugate-gsk227-receives-us-fda-breakthrough-therapy-designation-in-late-line-relapsed-or-refractory-osteosarcoma"}]},"stickyShare":null,"exitSitePreferences":{"popupEnabled":true,"title":"You are leaving our website","texts":"

The information you are about to be referred to may not comply with the local regulatory requirements. Further information relevant to the local environment is available from the company or via the Product Information.

","continueText":"Continue","cancelText":"Cancel","exclusionUrls":["https://www.gsk.com","https://www.facebook.com/GSK","http://doingmoreintheus.gsk.com/en-us/map-regions/","https://www.gsk.com/en-gb","https://www.gsk.com/en-gb/investors/quarterly-results/","https://www.gsk.com/en-gb/about-us/vaccines/why-you-don-t-outgrow-vaccination/","https://www.gsk.com/en-gb/behind-the-science/patients-consumers/eggs-in-manufacturing/","https://innovation.gsk.com/","http://doingmoreintheus.gsk.com/en-us/map-regions/north-carolina/doing-more-on-moore-drive-in-the-research-triangle-park/","http://doingmoreintheus.gsk.com/en-us/map-regions/pennsylvania/gsk-navy-yard-where-we-do-more-with-less/","https://www.gsk.com/en-gb/about-us/save-the-children-partnership","https://www.gskgrants.com","https://www.gskforyou.com/","http://fortherecord.payments.us.gsk.com","https://www.gsk-clinicalstudyregister.com/","https://www.gsk.com/en-gb/about-us/policies-codes-and-standards/","http://www.gsk.com/en-gb/about-us/policies-codes-and-standards/","https://www.gsk.com/en-gb/products/stiefel-dermatology/","https://www.gsk.com/en-gb/products/viiv-healthcare/","https://www.contactus.gsk.com/callback/index.html","https://www.gsksource.com/gskprm/en/US/adirect/gskprm?cmd=Home&entryPoint=adirect&messageType=Home","https://www.gsksource.com/pharma/content/gsk/source/us/en.html","http://www.msds-gsk.com/","https://www.gsk.com/en-gb/investors/shareholder-information/","http://www.gsk.com/en-gb/investors/","https://www.gsk.com/en-gb/investors/corporate-reporting/","https://www.gsk.com/en-gb/investors/product-pipeline/","http://www.gskgrants.com/","https://www.gsksource.com/gskprm/en/US/adirect/gskprm?cmd=Home&entryPoint=adirect&messageType=Home","https://www.gsk.com/media/2941/human-rights-statement-policy.pdf","http://www.gsk.com/media/280848/human-rights-statement-policy.pdf","http://www.gsk.com/en-gb/research/rd-locations/pharmaceuticals/","https://www.gsk.com/en-gb/business-to-business/","https://supplier.gsk.com/irj/portal/public?guest_user=SUP_GUEST_EN","https://www.gsk.com/en-gb/business-to-business/","https://supplier.gsk.com/irj/portal/public?guest_user=SUP_GUEST_EN","http://twitter.com/GSK","http://www.youtube.com/GSK","http://www.flickr.com/photos/glaxosmithkline","http://www.linkedin.com/company/glaxosmithkline","https://www.instagram.com/gsk/ ","http://www.gsk-clinicalstudyregister.com/","https://www.gsk.com/en-gb/media/press-releases/new-multi-country-survey-reveals-need-for-improved-awareness-around-long-term-impact-and-appropriate-use-of-corticosteroids-in-sle-management/","https://www.gsk.com/en-gb/behind-the-science/our-people/from-tv-to-tackling-lupus-why-alex-moved-from-media-to-medicine/","http://www.gskforyou.com/","http://us.gsk.com/en-us/behind-the-science/?tag=Corporate+responsibility","https://www.gskforyou.com/prescription-resource-assistance/immunology-respiratory/","https://www.contactus.gsk.com/callback.html","https://www.gsk.com/en-gb/about-us/governance/global-compliance/","https://www.gsk.com/en-gb/careers/physicians/","https://www.gsk.com/en-gb/careers/job-finder/","https://www.gsk.com/en-gb/contact-us/worldwide/","https://access.gsk.com/password/","https://access.gsk.com/selfservice/static/login.jsp?TYPE=33554433&REALMOID=06-c7edf5ec-5585-100d-83b1-84797f88fc89&GUID=&SMAUTHREASON=0&METHOD=GET&SMAGENTNAME=-SM-90R5K5a0NsTyKRhPyTIn3A3B5ovKkqcehflGRUrUNusjZdRaPY%2bWUozEFizs1bMg&TARGET=-SM-https%3a%2f%2fuksah%2egsk%2ecom%2fswh_uk_win_ns%2fcommunications%2femployee%2femployees%2ehtm","https://www.gsk.com/en-gb/responsibility/operating-responsibly/working-with-third-parties/","https://supplier.gsk.com/irj/portal/public?guest_user=SUP_GUEST_EN","https://ascend.cvmsolutions.com/Account/Login?client=gsk","https://twitter.com/GSKUS","https://twitter.com/GSK","https://www.gsk.com/media/5097/our-approach-to-responsible-business_sept-18.pdf","https://www.gsk.com/en-gb/responsibility/responsibility-reports-data/","https://www.gsk.com/media/2538/gsk-materiality-process.pdf","https://www.gsk.com/en-gb/responsibility/access-to-healthcare/","https://www.gsk.com/en-gb/responsibility/our-people/","https://www.gsk.com/en-gb/responsibility/environment/","https://www.gsk.com/en-gb/responsibility/operating-responsibly/","https://www.gsk.com/media/4552/our-code-of-practice.pdf","https://www.gsk.com/media/4552/our-code-of-practice.pdf#page=10","https://www.gsk.com/media/4552/our-code-of-practice.pdf#page=35","https://www.gsk.com/media/4552/our-code-of-practice.pdf#page=35","https://www.instagram.com/gsk/","https://twitter.com/gsk","https://twitter.com/gskus","https://www.youtube.com/GSK","https://www.gsk.com/en-gb/media/resource-centre/","https://www.gsk.com/en-gb/media/image-and-video-library/","https://www.gsk.com/en-gb/media/rss-feeds/","https://www.gsk.com/en-gb/investors/corporate-reporting/annual-report-2017/","https://www.gsk.com/en-gb/careers/experienced-professionals/business-operations/","https://www.gsk.com/en-gb/careers/experienced-professionals/engineering/","https://www.gsk.com/en-gb/careers/experienced-professionals/manufacturing-and-supply/","https://www.gsk.com/en-gb/careers/experienced-professionals/marketing-and-communications/","https://www.gsk.com/en-gb/careers/experienced-professionals/research-and-development/","https://www.gsk.com/en-gb/careers/experienced-professionals/sales/","https://www.gsk.com/media/5041/rd-update-slides-hal-barron.pdf","https://www.gsk.com/en-gb/careers/meet-our-people/","https://www.gsk.com/en-gb/responsibility/our-people/employee-volunteering/","https://www.gsk.com/en-gb/careers/postgraduate-opportunities/","https://gskearlytalent.avature.net/landingpage","https://www.gsk.com/en-gb/careers/apprentices-students-and-graduates/future-leaders-graduate-programme/","https://www.gsk.com/en-gb/responsibility/our-people/volunteer-stories/","https://www.gsk.com/en-gb/partnerships/bioelectronics-research-network/","https://www.gsk.com/en-gb/research/our-approach/open-innovation/","https://www.gsk.com/en-gb/careers/careers-search/?r=USA","https://www.linkedin.com/company/gsk-canada/","https://www.linkedin.com/company/gsk_consumer_healthcare_india/","https://www.linkedin.com/company/gsk-pharmaceuticals-india/","https://www.linkedin.com/company/glaxosmithkline-poland/","https://www.youtube.com/user/gskasiachannel/","https://www.youtube.com/channel/UChWuz9ZDceHYHXmJVJ4hF8Q","https://www.youtube.com/channel/UCN1XeWQWLVhFLHQwZl93jFQ","https://www.youtube.com/channel/UCwQyIfV4pLlsZGuN7fiZm2w","https://twitter.com/gsk_ar","https://twitter.com/GSK_Asia","https://twitter.com/gsk_conferences","https://twitter.com/gsk_au","https://twitter.com/GSK_DE","https://twitter.com/GSKCH_INDIA","https://twitter.com/GSK_IE","https://twitter.com/gsk_it","https://twitter.com/GSKScience","https://twitter.com/stiefel","https://www.gsk.com/en-gb/media/press-releases/karenann-terrell-appointed-chief-digital-technology-officer-gsk/","https://www.gsk.com/en-gb/behind-the-science/innovation/the-digitalisation-lab-bringing-the-digital-age-to-manufacturing/","https://www.gsk.com/en-gb/careers/meet-our-people/lindsay-rd-uk/","http://uk.gsk.com/en-gb/careers/apprenticeships/","https://www.gsk.com/media/4931/gsk-quick-facts.pdf","https://ie.gsk.com/ie/careers/apprenticeships/","http://au.gsk.com/en-au/careers/apprenticeships/","http://sg.gsk.com/en-sg/careers/","https://www.gsk.com/en-gb/contact-us/report-a-possible-side-effect/","https://gsk.i-sight.com/landing-page/","https://www.gskforyou.com/","https://jobs.gsk.com/en-us/jobs?keywords=RichmondConsumerHealthcareR%26D&page=1","https://jobs.gsk.com/en-us/jobs?page=1&location=Lincoln,%20NE,%20United%20States&woe=7&stretch=10&stretchUnit=KILOMETERS&keywords=manufacturing&sortBy=relevance","https://jobs.gsk.com/en-us/jobs?page=1&location=Carlisle,%20PA,%20United%20States&woe=7&stretch=10&stretchUnit=KILOMETERS&keywords=manufacturing&sortBy=relevance","https://jobs.gsk.com/en-us/jobs?page=1&location=East%20Durham,%20NY,%20United%20States&woe=7&stretch=10&stretchUnit=KILOMETERS&keywords=manufacturing&sortBy=relevance","https://us.gsk.com/en-us/media/press-releases/fda-approves-parp-inhibitor-in-first-line-monotherapy-maintenance-treatment-for-women-with-platinum-responsive-advanced-ovarian-cancer-regardless-of-biomarker-status/","https://privacy.gsk.com/en-us/privacy-notice/","https://www.gsk.com/en-gb/investors/corporate-reporting/annual-report-2020/","https://www.gsk.com/en-gb/careers/","https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-fy-2021-reported-sales-of-34-billion-stable-at-aer-plus5-cer/","https://www.gsk.com/en-gb/investors/financial-reports/annual-report-2021/","https://www.gsk.com/media/7473/esg-performance-report-2021.pdf","https://www.gsk.com/en-gb/company/codes-standards-and-reports/","https://www.gsk.com/en-gb/investors/","https://www.gsk.com/en-gb/media/our-response-to-covid-19/","https://www.gsk.com/en-gb/behind-the-science-magazine/","https://www.gsk.com/en-gb/media/","https://www.gsk.com/en-gb/behind-the-science/","https://gskpro.com/","https://viivhealthcare.com/","https://www.gsk-studyregister.com/en/","https://gsk.supplierone.co/","https://www.gsk.com/en-gb/investors/financial-reports/","https://www.gsk.com/en-gb/investors/dividend-and-share-price/","https://www.gsk.com/en-gb/innovation/pipeline/","https://www.gsk.com/speakup","https://www.gsk.com/en-gb/company/outstanding-people/","https://www.gsk.com/en-gb/company/policy-positions","https://www.gsk.com/en-gb/research-and-development/our-approach-to-rd/","https://www.gsk.com/en-gb/innovation/partnerships/","https://www.gsk.com/media/8519/the-code-printable-version.pdf","https://www.gsk.com/en-gb/company/policy-positions/#","https://www.gsk.com/en-gb/innovation/therapeutic-areas/infectious-diseases/","https://www.gsk.com/en-gb/innovation/therapeutic-areas/hiv/","https://www.gsk.com/en-gb/innovation/therapeutic-areas/oncology/","https://www.gsk.com/en-gb/innovation/therapeutic-areas/immunology/","https://www.gsk.com/en-gb/innovation/therapeutic-areas/opportunity-driven/","https://www.togetherwithgskoncology.com/","https://www.gsk.com/en-gb/behind-the-science/looking-deeper-into-lupus/","https://gateway.on24.com/wcc/eh/3471076/Patient+Engagement+Hub","https://www.gsk.com/en-gb/behind-the-science/following-the-science-of-oxygen-to-discover-solutions-for-anaemia/","https://www.multivu.com/players/English/8857131-gsk-ask2bsure-meningitis-b-vaccination/","https://www.gsk.com/en-gb/innovation/rd-locations/","https://www.gsk.com/en-gb/innovation/research-and-development-approach/","https://www.gsk.com/en-gb/innovation/research-and-development-approach/","https://www.gsk.com/en-gb/innovation/","https://www.gsk.com/en-gb/behind-the-science/mrna-messenger-ribonucleic-acid-disrupting-the-field-of-vaccinology/","https://www.gsk.com/en-gb/behind-the-science/inside-the-vaccine-factory-of-the-future/","https://www.gsk-studyregister.com/","https://www.gsk.com/en-gb/responsibility/global-health-and-health-security/","https://www.gsk.com/en-gb/responsibility/pricing-and-access/","https://www.gsk.com/en-gb/responsibility/global-health-and-health-security/","https://www.gsk.com/en-gb/responsibility/diversity-equity-and-inclusion/","https://www.gsk.com/en-gb/responsibility/environmental-sustainability/","https://www.gsk.com/en-gb/responsibility/product-governance/","https://www.gsk.com/en-gb/responsibility/ethical-standards/","https://www.gsk.com/media/8518/policies-and-standards.pdf","https://www.gsk.com/en-gb/company/governance/compliance/","https://www.gsk.com/en-gb/responsibility/ethical-standards/working-with-third-parties/","https://www.gsk.com/en-gb/responsibility/ethical-standards/public-policy-and-patient-advocacy/","https://www.gsk.com/en-gb/responsibility/ethical-standards/human-rights/","https://www.gsk.com/en-gb/responsibility/ethical-standards/use-of-animals/","https://www.gsk.com/en-gb/responsibility/ethical-standards/engaging-with-healthcare-professionals/","https://www.gsk.com/en-gb/media/press-releases/","https://annualreport.gsk.com/","https://www.gsk.com/en-gb/media/media-contacts/","https://www.gsk.com/en-gb/media/media-library/","https://www.gsk.com/en-gb/media/social-media/","https://www.gsk.com/en-gb/media/our-response-to-the-situation-in-ukraine/","https://jobs.gsk.com/en-us/jobs?keywords=%23ApprenticeUS&location=&lang=en-us","https://www.gsk.com/en-gb/behind-the-science/advancing-the-next-generation-of-immuno-oncology/","https://www.gsk.com/en-gb/behind-the-science/synthetic-lethality-outmanoeuvring-the-cancer-genome/","https://www.gsk.com/en-gb/media/press-releases/gsk-and-lyell-immunopharma-join-forces-to-develop-the-next-generation-of-cancer-cell-therapies/","https://jobs.gsk.com/en-us/jobs?keywords=oncology&page=1","https://jobs.gsk.com/en-us/jobs?keywords=oncology&page=1","https://www.gsk.com/en-gb/research-and-development/our-pipeline/","https://jobs.gsk.com/en-us/jobs?keywords=%23WYARD2022&location=&lang=en-us","https://jobs.gsk.com/en-us/jobs?keywords=%23WYAcommerical2022&lang=en-us&sortBy=relevance&page=1","https://jobs.gsk.com/en-us/jobs?keywords=%23WYAGSC2022&lang=en-us&sortBy=relevance&page=1","https://jobs.gsk.com/en-us/jobs?lang=en-us&sortBy=relevance&page=1&location=United%20States&woe=12&stretchUnit=MILES&stretch=10","https://www.gsk.com/media/8520/the-code-presentation-version.pdf","https://www.gsk.com/en-gb/careers/featured-careers/","https://www.gsk.com/en-gb/careers/how-we-hire/","https://www.gsk.com/en-gb/careers/our-global-and-regional-hubs/","https://www.gsk.com/en-gb/careers/how-we-hire/frequently-asked-questions/","https://supplier.gsk.com/irj/portal/public","http://www.gsk.com/en-gb/contact-us/worldwide/","https://www.gsk.com/en-gb/contact-us/report-a-possible-side-effect/enquiries-privacy-notice/","https://gskpro.com/en-us/","https://gskpro.com/","https://gskpro.com","https://www.gsk.com/en-gb/responsibility/esg-resources/","http://www.gskfunding.com/","https://www.gsk.com/en-gb/behind-the-science-magazine/prevention-best-medicine-disease-patients/","https://www.gsk.com/en-gb/behind-the-science-magazine/men-women-gender-diversity-clinical-trials/","https://www.gsk.com/en-gb/behind-the-science-magazine/maps-technology-new-age-vaccine-development-infectious-diseases/","https://www.gsk.com/en-gb/investors/speeches-and-presentations/","https://www.gsk.com/en-gb/responsibility/environment/climate/","https://contactus.gsk.com/","https://gsk.connectr.co.uk/getahead/","https://www.linkedin.com/company/gsk/","https://x.com/GSKUS?mx=2","https://www.facebook.com/GSK/","https://jobs.gsk.com/?lang=en-us&previousLocale=en-US","https://jobs.gsk.com/en-us/jobs?keywords=%23USCommercialDevelopmentProgram&page=1&sortBy=relevance?keywords=%23USCommercialDevelopmentProgram&page=1&sortBy=relevance&location=United%20States","https://jobs.gsk.com/?lang=en-us&previousLocale=en-US","https://jobs.gsk.com/en-us/jobs?keywords=&location=&lang=en-us?keywords=%23ApprenticeUS2026&page=1&sortBy=relevance&location=United%20States&stretch=10&stretchUnit=MILES?keywords=%23ApprenticeUS2025%20&page=1&sortBy=relevance&location=United%20States","https://www.vaccinetrack.com/Trend?tab=gap&vaccine=9&timePeriod=2021","https://jobs.gsk.com/en-us/jobs?keywords=&location=&lang=en-us","http://tinyurl.com/mrt9buj2","https://jobs.gsk.com/en-gb/jobs?location=Massachusetts,%20United%20States&locations=Boston,Massachusetts,United%20States%7CCambridge,Massachusetts,United%20States%7CWaltham,Massachusetts,United%20States&page=1&stretch=10&stretchUnit=MILES&woe=8","https://jobs.gsk.com/en-us/jobs?keywords=%23USCommercialDevelopmentProgram&sortBy=relevance&page=1&location=United%20States&woe=12®ionCode=US&stretchUnit=MILES&stretch=50","https://jobs.gsk.com/en-us/jobs?keywords=%23USCommercialDevelopmentProgram&page=1&sortBy=relevance&location=United%20States?keywords=%23ApprenticeUS&location=&lang=en-us","https://x.com/GSKUS","https://ourwayforward.com/content/dam/brs-pharma-us/ourwayforward-dtc/en_US/pdfs/oc-patient-discussion-guide.pdf","https://gsk.public.reportum.com/","https://password.gsk.com/password/","https://uksah.gsk.com/swh_uk_win_ns/communications/employee/employees.htm","https://www.vaccinetrack.com/Trend?tab=gap&timePeriod=2022&timePeriod2=2021","https://gskvaccination.com/","https://jobs.gsk.com/en-gb/jobs?lang=en-gb&page=1&location=Massachusetts,%20United%20States&woe=8&stretchUnit=MILES&stretch=10&locations=Boston,Massachusetts,United%20States%7CCambridge,Massachusetts,United%20States%7CWaltham,Massachusetts,United%20States&utm_source=direct&utm_campaign=25453&utm_medium=symphonytalent-misctags&utm_term=43516_Boston%20In-House","https://dontbeembarrassed.com/","https://www.vaccinetrack.com","https://scienceinthesummer.fi.edu/","https://jobs.gsk.com/en-gb/jobs?location=United%20States&locations=Boston,Massachusetts,United%20States%7CCambridge,Massachusetts,United%20States%7CWaltham,Massachusetts,United%20States&page=1&stretch=10&stretchUnit=MILES&woe=8"]},"settings":{"optionalStylesheetLink":null,"themeColorHexCode":null,"headerLogoLightTheme":null,"headerLogoDarkTheme":null,"footerLogo":{"src":"https://us.gsk.com/media/kzafk31i/gsk-logo.png?width=104&format=webp&quality=100&v=1dbe12293a58ec0","alt":"Gsk Logo (1)","darkModeSrc":"https://us.gsk.com/media/kzafk31i/gsk-logo.png?width=104&format=webp&quality=90&v=1dbe12293a58ec0"},"scripts":[{"pageLocation":"Top","text":" \n"}],"globalWebsiteLink":{"text":"Global","href":"https://www.gsk.com","target":"_blank","openInNewWindowText":"Opens in a new window"},"googleMapsApiKey":"AIzaSyA2QMg4Ww6djPKb7b9BraQn4kgJmDaLblg","textToSpeechApiKey":"70ab0a79-1d92-4286-86d2-abdd71cc785c","bingVerificationCode":"","googleAnalytics":"","siteTitle":" | GSK US"},"pageSettings":{"disableBackToTopButton":false,"backToTopButtonText":"Back to top","robotsNoFollow":false,"robotsNoIndex":false,"canonicalUrl":"https://us.gsk.com/en-us/media/press-releases/gsk-b7-h3-targeted-antibody-drug-conjugate-gsk227-receives-us-fda-breakthrough-therapy-designation-in-late-line-relapsed-or-refractory-osteosarcoma/"},"tealiumSettings":{"enabled":false,"data":""},"entryPopup":null,"protectedPage":false,"schema":null}